

	Cost containment of global monoclonal antibody drugs and cancer clinical trials via LLM focused reasoning	
	Kevin Kawchak	
	Chief Executive Officer	
	ChemicalQDevice	
	San Diego, CA	
	February 25, 2025	
	kevink@chemicalqdevice.com	
	Traceability Part B TRB Human-in-the-Loop Verification, Scope = Financial Verifications of ChatGPT o3-mini.	
	The content is available under CC BY 4.0. Refer to manuscript Table 2 for article references. (Pages 1-8)	
	<u>Generation B1: Four Page Report on 15 “Global mAb Cancer Cost” Summaries</u>	
	<u>Executive Summary</u>	
	3.5 Sonnet 15 Global Summaries	
1	Pre-biosimilar reference product mean OOP cost: "\$911" (Feng K. et al.) Post-biosimilar mean OOP cost: "\$707" (Feng K. et al.)	o3-mini LLM Author and Quote
	"Feng K. et al. 2024"	
	mean out-of-pocket costs declined from "\$911" to "\$707"	
Y	In-Context	
	3.5 Sonnet 15 Global Summaries	
2	Bevacizumab biosimilar claims had 21% higher OOP costs than the reference product	o3-mini LLM Author and Quote
	"Feng K. et al. 2024"	
	biosimilar bevacizumab claims had 21% higher patient spending	
Y	In-Context	
	3.5 Sonnet 15 Global Summaries	
3	- Rituximab biosimilar claims showed 10% lower OOP costs - Trastuzumab biosimilar claims demonstrated 8% lower OOP costs	o3-mini LLM Author and Quote
	"Feng K. et al. 2024"	
	biosimilar rituximab and trastuzumab claims reduced costs by 10% and 8%, respectively	
Y	In-Context	
	3.5 Sonnet 15 Global Summaries	
4	- Bevacizumab: "\$110" per dose reduction - Trastuzumab: "\$438" per dose reduction	o3-mini LLM Author and Quote
	"Chen H. et al. 2024"	
	per-dose price reductions for bevacizumab and trastuzumab of "110"and"438"	
Y	In-Context	
	3.5 Sonnet 15 Global Summaries	
5	was associated with a 9.2% increase in biosimilar prescriptions	o3-mini LLM Author and Quote
	"Itoshima H. et al. 2024"	
	biosimilar uptake by 9.2% for rituximab, trastuzumab, and bevacizumab	
Y	In-Context	
	3.5 Sonnet 15 Global Summaries	
6	The financial incentive of "\$10.4" per patient per month for up to 3 months	o3-mini LLM Author and Quote
	"Itoshima H. et al. 2024"	
	with modest incentive costs of "\$10.4" per patient per month	
Y	In-Context	
	3.5 Sonnet 15 Global Summaries	
7	Biosimilar versions were priced 40-60% lower than reference products	o3-mini LLM Author and Quote
	"Itoshima H. et al. 2024"	
	biosimilar pricing between 40% and 60% of reference products	
Y	In-Context	

		3.5 Sonnet 15 Global Summaries
8	Mean costs were "€1,718.27" for IV Herceptin®, "€1,620.66" for subcutaneous Herceptin®, and "€987.97" for biosimilars	
		o3-mini LLM Author and Quote
	Kirshner G. et al. 2024"	
	converted from "€1,718.27", "€1,620.66", and "€987.97" respectively;	
Y	In-Context, Note: 1.1 USD to EUR	
		3.5 Sonnet 15 Global Summaries
9	The study found that biosimilar uptake reached 27% market share	
		o3-mini LLM Author and Quote
	"Wu Q. et al. 2024"	
	biosimilar trastuzumab uptake reached 27%	
Y	In-Context	
		3.5 Sonnet 15 Global Summaries
10	- Original trastuzumab pricing declined from "\$3,500/440mg" to "\$800/440mg" after negotiations - Switching to biosimilars led to average cost savings of "\$421.11" per treatment course for HER2-positive breast cancer patients	
		o3-mini LLM Author and Quote
	"Wu Q. et al. 2024"	
	negotiations reduced originator pricing from "\$3,500/440mg" to "\$800/440mg", resulting in an average saving of "\$421.11" per treatment course	
Y	In-Context	
		3.5 Sonnet 15 Global Summaries
11	- Mean total one-year cost savings of "\$6,379" per patient with biosimilars	
		o3-mini LLM Author and Quote
	"Lu B. et al. 2024"	
	reported one-year per-patient savings of "\$6,379	
Y	In-Context	
		3.5 Sonnet 15 Global Summaries
12	- 62% reduction in non-drug consumables costs, saving "\$999" per patient annually - Total annual savings of "\$5,727" per patient when including all direct and indirect costs	
		o3-mini LLM Author and Quote
	"Figallo M. et al. 2024"	
	reduced non-drug consumable costs by "\$999" per patient annually and yielded total annual savings of "\$5,727" while also saving significant healthcare professional time	
Y	In-Context	
		3.5 Sonnet 15 Global Summaries
13	- TDM1 provided an incremental 1.59 quality-adjusted life years (QALYs) at an additional cost of "\$1,408" compared to trastuzumab - The incremental cost-effectiveness ratio (ICER) was "\$886" per QALY gained, below Iran's threshold of "\$1,085" per QALY	
		o3-mini LLM Author and Quote
	"Hemati H. et al. 2024"	
	Markov model comparing trastuzumab+emtansine to trastuzumab revealed an incremental cost of "\$1,408" with an incremental cost-effectiveness ratio of "\$886" per quality-adjusted life year gained	
Y	In-Context	
		3.5 Sonnet 15 Global Summaries
14	The analysis demonstrates that SC administration reduces total treatment costs by approximately \$4,071.72 over a full 18-cycle treatment course compared to IV administration	
		o3-mini LLM Author and Quote
	"Otoya I. et al. 2024"	
	subcutaneous administration of trastuzumab was found to reduce overall treatment costs by "\$4,071.72" per complete treatment course compared to intravenous administration	
Y	In-Context	
		3.5 Sonnet 15 Global Summaries
15	- Calculated cost-based prices were significantly lower than current list prices for pembrolizumab, ranging from "\$52 to \$885" per vial compared to list prices of "\$2,861" in the Netherlands and "\$5,350" in the US	
		o3-mini LLM Author and Quote
	"Heine R. et al. 2024"	
	estimated cost-justified prices for pembrolizumab and daratumumab that were substantially lower than current list price	
Y	In-Context, Approximation	
		3.5 Sonnet 15 Global Summaries
16	- Keytruda (pembrolizumab) generated revenue of "\$17.321 billion" in 2021, with the cost per patient reaching "\$175,000" per year	
		o3-mini LLM Author and Quote

	"Whitacre R. et al. 2024"
	such as pembrolizumab, which has generated annual revenues of "\$17.321 billion" and costs of approximately "\$175,000" per patient per year
Y	In-Context
	3.5 Sonnet 15 Global Summaries
17	- First-line pembrolizumab treatment increased mean per-patient costs by EUR 11,497 compared to pre-immunotherapy chemotherapy
	o3-mini LLM Author and Quote
	"Gentili N. et al. 2024"
	(converted from "€11,497") compared to chemotherapy
Y	In-Context, Note: 1.1 USD to EUR
	<u>Technical Details</u>
	3.5 Sonnet 15 Global Summaries
18	- Claims analyzed: Over 1.7 million total claims
	o3-mini LLM Author and Quote
	"Feng K. et al. 2024"
	One study analyzed over 1.7 million claims
Y	In-Context
	3.5 Sonnet 15 Global Summaries
19	based on analysis of pricing data across 57 countries
	o3-mini LLM Author and Quote
	"Chen H. et al. 2024"
	Pharmaceutical sales data from 57 countries
Y	In-Context
	3.5 Sonnet 15 Global Summaries
20	The impact of financial incentives promoting biosimilar products in oncology: A quasiexperimental study using administrative data
	o3-mini LLM Author and Quote
	"Itoshima H. et al. 2024"
	evaluated the impact of financial incentives on biosimilar adoption in Japan
Y	In-Context
	3.5 Sonnet 15 Global Summaries
21	Mean costs were "€1,718.27" for IV Herceptin®, "€1,620.66" for subcutaneous Herceptin®, and "€987.97" for biosimilars
	o3-mini LLM Author and Quote
	"Kirshner G. et al. 2024"
	treatment cost estimates of approximately "\$1,889" for intravenous and "\$1,783" for subcutaneous formulations compared to "\$1,087" for biosimilars
Y	In-Context, Note: 1.1 USD to EUR
	3.5 Sonnet 15 Global Summaries
22	- Monthly consumption data from 2,253 representative hospitals across 30 Chinese provinces
	o3-mini LLM Author and Quote
	"Wu Q. et al. 2024"
	monthly consumption data from over 2,200 hospitals in China provided insights into biosimilar uptake and price negotiations for trastuzumab
Y	In-Context
	3.5 Sonnet 15 Global Summaries
23	- Mean total one-year cost savings of "\$6,379" per patient with biosimilars
	o3-mini LLM Author and Quote
	"Lu B. et al. 2024"
	identifying per-patient savings of "\$6,379" over one year
Y	In-Context
	3.5 Sonnet 15 Global Summaries
24	- 62% reduction in non-drug consumables costs, saving "\$999" per patient annually - Total annual savings of "\$5,727" per patient when including all direct and indirect costs
	o3-mini LLM Author and Quote
	"Figallo M. et al. 2024"
	compared fixed-dose combination pertuzumab–trastuzumab to separate intravenous infusions, quantifying savings in consumables, professional time, and indirect costs
Y	In-Context, Approximation, Repetition
	3.5 Sonnet 15 Global Summaries
25	- TDM1 provided an incremental 1.59 quality-adjusted life years (QALYs) at an additional cost of "\$1,408" compared to trastuzumab - The incremental cost-effectiveness ratio (ICER) was "\$886" per QALY gained, below Iran's threshold of "\$1,085" per QALY

		o3-mini LLM Author and Quote
		"Hemati H. et al. 2024
		yielding an incremental cost of "\$1,408" and an ICER of "\$886" per QALY
Y		In-Context, Repetition
		3.5 Sonnet 15 Global Summaries
26		The analysis demonstrates that SC administration reduces total treatment costs by approximately \$4,071.72 over a full 18-cycle treatment course compared to IV administration
		o3-mini LLM Author and Quote
		"Otoya I. et al. 2024
		compared subcutaneous versus intravenous administration of trastuzumab and documented an overall cost saving of "\$4,071.72" per treatment course
Y		In-Context, Repetition
		3.5 Sonnet 15 Global Summaries
27		- Calculated cost-based prices were significantly lower than current list prices for pembrolizumab, ranging from "\$52 to \$885" per vial compared to list prices of "\$2,861" in the Netherlands and "\$5,350" in the US
		o3-mini LLM Author and Quote
		"Heine R. et al. 2024
		to derive cost-based price ranges for pembrolizumab and daratumumab, with estimated per-vial prices ranging from "\$52" to "\$885" for pembrolizumab and a comparable range for daratumumab
Y		In-Context, Repetition
		3.5 Sonnet 15 Global Summaries
28		- Keytruda (pembrolizumab) generated revenue of "\$17.321 billion" in 2021, with the cost per patient reaching "\$175,000" per year
		o3-mini LLM Author and Quote
		"Whitacre R. et al. 2024
		Longitudinal revenue data and clinical trial timelines provided insight into how cost pressures and regulatory strategies affect pricing and patient access, as demonstrated by analyses of therapies such as pembrolizuma
Y		In-Context, Approximation, Repetition
		3.5 Sonnet 15 Global Summaries
29		- First-line pembrolizumab treatment increased mean per-patient costs by EUR 11,497 compared to pre-immunotherapy chemotherapy
		o3-mini LLM Author and Quote
		"Gentili N. et al. 2024
		revealing that first-line pembrolizumab increased per-patient costs by approximately "\$12,647" (converted from "C11,497") while demonstrating improved survival outcomes
Y		In-Context, Repetition
		Key Insights
		3.5 Sonnet 15 Global Summaries
30		- Bevacizumab: "\$110" per dose reduction - Trastuzumab: "\$438" per dose reduction
		o3-mini LLM Author and Quote
		"Chen H. et al. 2024
		decreases of "\$110" per dose for bevacizumab and "\$438" per dose for trastuzumab
Y		In-Context, Repetition
		3.5 Sonnet 15 Global Summaries
31		Bevacizumab biosimilar claims had 21% higher OOP costs than the reference product
		o3-mini LLM Author and Quote
		"Feng K. et al. 2024
		may incur higher out-of-pocket expenses compared to the reference product, whereas rituximab and trastuzumab biosimilars tend to lower cost
Y		In-Context, Approximation, Repetition
		3.5 Sonnet 15 Global Summaries
32		The financial incentive of "\$10.4" per patient per month for up to 3 months
		o3-mini LLM Author and Quote
		"Itoshima H. et al. 2024
		even modest amounts like "\$10.4" per patient monthly, can effectively shift prescribing toward biosimilars, thereby potentially lowering overall expenditure
Y		In-Context, Repetition
		3.5 Sonnet 15 Global Summaries
33		Mean costs were "€1,718.27" for IV Herceptin®, "€1,620.66" for subcutaneous Herceptin®, and "€987.97" for biosimilars
		o3-mini LLM Author and Quote
		"Kirshner G. et al. 2024
		with biosimilar trastuzumab averaging approximately "\$1,087" compared to higher costs for proprietary formulations
Y		In-Context, Note: 1.1 USD to EUR

	3.5 Sonnet 15 Global Summaries
34	- Mean total one-year cost savings of "\$6,379" per patient with biosimilars
	o3-mini LLM Author and Quote
	"Lu B. et al. 2024
	as demonstrated by savings of "\$6,379" per patient in metastatic colorectal cancer when using bevacizumab biosimilars
Y	In-Context, Approximation, Repetition
	3.5 Sonnet 15 Global Summaries
35	- 62% reduction in non-drug consumables costs, saving "\$999" per patient annually - Total annual savings of "\$5,727" per patient when including all direct and indirect costs - The analysis demonstrates that SC administration reduces total treatment costs by approximately \$4,071.72 over a full 18-cycle treatment course compared to IV administration
	o3-mini LLM Author and Quote
	"Figallo M. et al. 2024; "Otoya I. et al. 2024
	fixed-dose combination therapies and subcutaneous formulations have been shown to reduce both direct and indirect costs, with savings ranging from "\$999" in consumables to a total of "\$5,727" annually per patient and overall treatment course savings of "\$4,071.72"
Y	In-Context, Repetition
	3.5 Sonnet 15 Global Summaries
36	The authors developed and tested pricing models incorporating research & development costs, manufacturing expenses, eligible patient populations, and profit margins to estimate sustainable pricing as indications expand.
	o3-mini LLM Author and Quote
	"Heine R. et al. 2024
	The analyses underscore that factors such as patient population size, R&D, and manufacturing costs are critical in establishing sustainable pricing
Y	In-Context
	3.5 Sonnet 15 Global Summaries
37	- Keytruda (pembrolizumab) generated revenue of "\$17.321 billion" in 2021, with the cost per patient reaching "\$175,000" per year
	o3-mini LLM Author and Quote
	"Whitacre R. et al. 2024
	Concurrently, high annual revenues—as seen with pembrolizumab generating "\$17.321 billion" and incurring costs of around "\$175,000" per patient—illustrate the financial pressures that can impede patient access
Y	In-Context
	3.5 Sonnet 15 Global Summaries
38	The analysis demonstrates that while immunotherapy introduction has increased absolute treatment costs, the survival benefits help justify the additional expenditure when considering monthly cost burden. Healthcare systems must balance access to innovative therapies with sustainable resource allocation.
	o3-mini LLM Author and Quote
	"Gentili N. et al. 2024
	Although the introduction of innovative therapies such as pembrolizumab has raised per-patient treatment costs, analyses from Italy indicate that improved survival outcomes and reductions in hospitalization may help balance the monthly cost burden
Y	In-Context
	<u>Generation B2: Financial Solutions to 15 “Global mAb Cancer Cost” Summaries</u>
	3.5 Sonnet 15 Global Summaries
39	The financial incentive of "\$10.4" per patient per month for up to 3 months
	o3-mini LLM Author and Quote
	Itoshima H. et al. 2024
	Implement modest incentive payments—such as a "\$10.4" per patient monthly payment (up to "\$31.2" per patient)—to encourage providers to prescribe biosimilars.
Y	In-Context
	3.5 Sonnet 15 Global Summaries
40	(e.g., bevacizumab 400mg biosimilar at "\$377.3" vs reference at "\$843.4")
	o3-mini LLM Author and Quote
	Itoshima H. et al. 2024
	Increase uptake of biosimilars that are priced 40–60% lower than their reference products (for example, a bevacizumab biosimilar priced at \$377.3 versus a reference product priced at "\$843.4").
Y	In-Context, In 15 Reports
	3.5 Sonnet 15 Global Summaries
41	- Calculated cost-based prices were significantly lower than current list prices for pembrolizumab, ranging from "\$52 to \$885" per vial compared to list prices of "\$2,861" in the Netherlands and "\$5,350" in the US
	o3-mini LLM Author and Quote
	Heine R. et al. 2024
	Use cost-based pricing models that have estimated prices for products such as pembrolizumab to range from "\$52" to "\$885" per vial, contrasting with current list prices that reach levels like "\$2,861" to "\$5,350."
Y	In-Context

	3.5 Sonnet 15 Global Summaries
42	- 62% reduction in non-drug consumables costs, saving "\$999" per patient annually - Total annual savings of "\$5,727" per patient when including all direct and indirect costs - The analysis demonstrates that SC administration reduces total treatment costs by approximately \$4,071.72 over a full 18-cycle treatment course compared to IV administration
	o3-mini LLM Author and Quote
	Figallo M. et al. 2024; Otoyá I. et al. 2024
	Emphasize fixed-dose combination therapies—for instance, using a fixed-dose combination of pertuzumab–trastuzumab, which has demonstrated annual savings of "\$5,727" per patient—and SC administration of trastuzumab that reduces total treatment course costs by \$4,071.72.
Y	In-Context
	3.5 Sonnet 15 Global Summaries
43	Pre-biosimilar reference product mean OOP cost: "\$911" (Feng K. et al.) Post-biosimilar mean OOP cost: "\$707" (Feng K. et al.)
	o3-mini LLM Author and Quote
	Feng K. et al. 2024
	Adjust policies so that when biosimilar entry reduces mean out-of-pocket costs from "\$911" to "\$707," the savings are reflected in reduced patient expenditures
Y	In-Context
	3.5 Sonnet 15 Global Summaries
44	for example, by ensuring that biosimilar trastuzumab, which averages a treatment cost of "\$1,087," can compete effectively against higher-priced subcutaneous and IV formulations
	o3-mini LLM Author and Quote
	Kirshner G. et al. 2024
	for example, by ensuring that biosimilar trastuzumab, which averages a treatment cost of "\$1,087," can compete effectively against higher-priced subcutaneous and IV formulations
Y	In-Context
	3.5 Sonnet 15 Global Summaries
45	- Mean total one-year cost savings of "\$6,379" per patient with biosimilars
	o3-mini LLM Author and Quote
	Lu B. et al. 2024
	Use findings such as per-patient savings of "\$6,379" with bevacizumab biosimilars in metastatic colorectal cancer to guide policy and reimbursement decisions
Y	In-Context
	3.5 Sonnet 15 Global Summaries
46	- could reduce carbon emissions by 21–26% for pembrolizumab
	o3-mini LLM Author and Quote
	Malmberg R. et al. 2024
	as evidenced by reductions of up to 21–26% in emissions for pembrolizumab
Y	In-Context, In 15 Reports
	<u>Generation B3: Table of Solutions to 15 “Global mAb Cancer Cost” Summaries</u>
	3.5 Sonnet 15 Global Summaries
47	- The financial incentive of "\$10.4" per patient per month for up to 3 months -Biosimilar versions were priced 40–60% lower than reference products -(e.g., bevacizumab 400mg biosimilar at "\$377.3" vs reference at "\$843.4")
	o3-mini LLM Author and Quote
	Itoshima H. et al. 2024
	Incentive payment of "\$10.4" per patient monthly (up to "\$31.2" per patient); biosimilars offered at 40–60% lower prices (e.g., a bevacizumab biosimilar priced at "\$377.3" versus a reference product priced at "\$843.4").
Y	In-Context, In 15 Reports
	3.5 Sonnet 15 Global Summaries
48	- Calculated cost-based prices were significantly lower than current list prices for pembrolizumab, ranging from "\$52 to \$885" per vial compared to list prices of "\$2,861" in the Netherlands and "\$5,350" in the US
	o3-mini LLM Author and Quote
	Heine R. et al. 2024
	Cost-based pricing estimates for pembrolizumab range from "\$52" to "\$885" per vial compared to current list prices ranging from "\$2,861" to "\$5,350."
Y	In-Context, In 15 Reports
	3.5 Sonnet 15 Global Summaries
49	- 62% reduction in non-drug consumables costs, saving "\$999" per patient annually - Total annual savings of "\$5,727" per patient when including all direct and indirect costs - The analysis demonstrates that SC administration reduces total treatment costs by approximately \$4,071.72 over a full 18-cycle treatment course compared to IV administration
	o3-mini LLM Author and Quote
	Figallo M. et al. 2024; Otoyá I. et al. 2024
	Fixed-dose combination pertuzumab–trastuzumab results in annual savings of "\$5,727" per patient; SC administration of trastuzumab reduces the total treatment course cost by "\$4,071.72."
Y	In-Context

	3.5 Sonnet 15 Global Summaries
50	Pre-biosimilar reference product mean OOP cost: "\$911" (Feng K. et al.) Post-biosimilar mean OOP cost: "\$707" (Feng K. et al.)
	o3-mini LLM Author and Quote
	Feng K. et al. 2024
	Mean out-of-pocket costs reduced from "\$911" to "\$707" after biosimilar entry
Y	In-Context
	3.5 Sonnet 15 Global Summaries
51	Mean costs were "€1,718.27" for IV Herceptin®, "€1,620.66" for subcutaneous Herceptin®, and "€987.97" for biosimilars
	o3-mini LLM Author and Quote
	Kirshner G. et al. 2024
	Biosimilar trastuzumab averages a treatment cost of "\$1,087" compared to higher prices for alternative subcutaneous and IV formulations.
Y	In-Context, Note: 1.1 USD to EUR
	3.5 Sonnet 15 Global Summaries
52	- Mean total one-year cost savings of "\$6,379" per patient with biosimilars
	o3-mini LLM Author and Quote
	Lu B. et al. 2024
	Observed per-patient savings of "\$6,379" with bevacizumab biosimilars in metastatic colorectal cancer.
Y	In-Context
	3.5 Sonnet 15 Global Summaries
53	- could reduce carbon emissions by 21-26% for pembrolizumab
	o3-mini LLM Author and Quote
	Malmberg R. et al. 2024
	Alternative dosing strategies for pembrolizumab can lead to emission reductions of 21–26%, indirectly reducing drug usage and associated costs.
Y	In-Context
	<u>Generation B4: Table of Forecasts to 15 “Global mAb Cancer Cost” Summaries</u>
	3.5 Sonnet 15 Global Summaries
54	(e.g., bevacizumab 400mg biosimilar at "\$377.3" vs reference at "\$843.4")
	o3-mini LLM Author and Quote
	Itoshima H. et al. 2024
	"\$377.3" per dose (biosimilar price)
Y	In-Context
	3.5 Sonnet 15 Global Summaries
55	- Calculated cost-based prices were significantly lower than current list prices for pembrolizumab, ranging from "\$52 to \$885" per vial
	o3-mini LLM Author and Quote
	Heine R. et al. 2024
	"\$52" to "\$885" per vial (cost-based forecast)
Y	In-Context
	3.5 Sonnet 15 Global Summaries
56	- Total annual savings of "\$5,727" per patient when including all direct and indirect costs
	o3-mini LLM Author and Quote
	Figallo M. et al. 2024
	Annual savings of "\$5,727" per patient
Y	In-Context
	3.5 Sonnet 15 Global Summaries
57	reduces total treatment costs by approximately \$4,071.72 over a full 18-cycle treatment course
	o3-mini LLM Author and Quote
	Otoya I. et al. 2024
	Reduction of "\$4,071.72" per treatment course
Y	In-Context
	3.5 Sonnet 15 Global Summaries
58	Post-biosimilar mean OOP cost: "\$707" (Feng K. et al.)
	o3-mini LLM Author and Quote
	Feng K. et al. 2024
	"\$707" per claim
Y	In-Context

	3.5 Sonnet 15 Global Summaries
59	Mean costs were "€1,718.27" for IV Herceptin®, "€1,620.66" for subcutaneous Herceptin®, and "€987.97" for biosimilars
	o3-mini LLM Author and Quote
	Kirshner G. et al. 2024
	Biosimilar trastuzumab at "\$1,087" per treatment
Y	In-Context, Note: 1.1 USD to EUR
	3.5 Sonnet 15 Global Summaries
60	- Mean total one-year cost savings of "\$6,379" per patient with biosimilars
	o3-mini LLM Author and Quote
	Lu B. et al. 2024
	Savings of "\$6,379" per patient annually
Y	In-Context
	3.5 Sonnet 15 Global Summaries
61	could reduce carbon emissions by 21-26% for pembrolizumab
	o3-mini LLM Author and Quote
	Malmberg R. et al. 2024
	21–26% reduction in emissions (indirect cost proxy)
Y	In-Context